CN1057522C - 作为前列腺素i2激动剂的萘衍生物 - Google Patents

作为前列腺素i2激动剂的萘衍生物 Download PDF

Info

Publication number
CN1057522C
CN1057522C CN95192846A CN95192846A CN1057522C CN 1057522 C CN1057522 C CN 1057522C CN 95192846 A CN95192846 A CN 95192846A CN 95192846 A CN95192846 A CN 95192846A CN 1057522 C CN1057522 C CN 1057522C
Authority
CN
China
Prior art keywords
expression
salt
compound
methyl
following formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN95192846A
Other languages
English (en)
Chinese (zh)
Other versions
CN1147250A (zh
Inventor
谷口清
长野正信
服部浩二
椿一典
冲津修
田渊精一郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9404734A external-priority patent/GB9404734D0/en
Priority claimed from GB9407036A external-priority patent/GB9407036D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of CN1147250A publication Critical patent/CN1147250A/zh
Application granted granted Critical
Publication of CN1057522C publication Critical patent/CN1057522C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Pyridine Compounds (AREA)
CN95192846A 1994-03-10 1995-03-08 作为前列腺素i2激动剂的萘衍生物 Expired - Fee Related CN1057522C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9404734A GB9404734D0 (en) 1994-03-10 1994-03-10 Heterocyclic compounds
GB9404734.7 1994-03-10
GB9407036A GB9407036D0 (en) 1994-04-08 1994-04-08 Naphthalene derivatives
GB9407036.4 1994-04-08

Publications (2)

Publication Number Publication Date
CN1147250A CN1147250A (zh) 1997-04-09
CN1057522C true CN1057522C (zh) 2000-10-18

Family

ID=26304472

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95192846A Expired - Fee Related CN1057522C (zh) 1994-03-10 1995-03-08 作为前列腺素i2激动剂的萘衍生物

Country Status (17)

Country Link
US (2) US5763489A (https=)
EP (1) EP0749424B1 (https=)
JP (1) JP3245864B2 (https=)
KR (1) KR100383305B1 (https=)
CN (1) CN1057522C (https=)
AT (1) ATE205479T1 (https=)
AU (1) AU688871B2 (https=)
CA (1) CA2185104A1 (https=)
DE (1) DE69522676T2 (https=)
DK (1) DK0749424T3 (https=)
ES (1) ES2160156T3 (https=)
GR (1) GR3037080T3 (https=)
HU (1) HU224822B1 (https=)
PT (1) PT749424E (https=)
RU (1) RU2155188C2 (https=)
TW (1) TW282456B (https=)
WO (1) WO1995024393A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2179399A1 (en) * 1993-12-20 1995-06-29 Kiyoshi Taniguchi 4,5-diaryloxazole derivatives
TW401408B (en) 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
DE19537548A1 (de) * 1995-10-09 1997-04-10 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19604191A1 (de) * 1996-02-06 1997-08-07 Hoechst Schering Agrevo Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
AUPO713297A0 (en) * 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
AUPP003297A0 (en) 1997-10-27 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds
AUPP029197A0 (en) * 1997-11-10 1997-12-04 Fujisawa Pharmaceutical Co., Ltd. Benzocycloheptene derivatives
AUPP109097A0 (en) 1997-12-22 1998-01-22 Fujisawa Pharmaceutical Co., Ltd. Napthalene derivatives
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
US20040127529A1 (en) * 1999-06-21 2004-07-01 Fujisawa Pharmaceutical Co., Ltd. Remedies for skin ulcer
AU5249200A (en) * 1999-06-21 2001-01-09 Fujisawa Pharmaceutical Co., Ltd. Remedies for skin ulcer
WO2002042243A1 (fr) * 2000-11-21 2002-05-30 Fujisawa Pharmaceutical Co., Ltd Processus de preparation de derives de tetrahydronaphtalene
JPWO2002085412A1 (ja) * 2001-04-18 2004-08-05 藤沢薬品工業株式会社 組織線維化抑制剤
ES2636943T3 (es) 2003-05-09 2017-10-10 Toray Industries, Inc. Beraprost y un inhibidor del sistema renina-angiotensina para usar en el tratamiento de enfermedades renales
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
ES2383239T3 (es) 2006-12-14 2012-06-19 Astellas Pharma Inc. Compuestos de ácidos policíclicos útiles como antagonistas de CRTH2 y como agentes antialérgicos
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
PL2203439T3 (pl) 2007-09-14 2011-06-30 Addex Pharmaceuticals Sa 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
KR20230085944A (ko) 2008-03-18 2023-06-14 아레나 파마슈티칼스, 인크. 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153912A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20220049612A (ko) 2014-01-21 2022-04-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
EP3977985B1 (en) 2017-03-01 2023-09-06 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
US12098116B2 (en) 2022-02-15 2024-09-24 United Therapeutics Corporation Crystalline prostacyclin (IP) receptor agonist and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542203A2 (en) * 1991-11-11 1993-05-19 Ono Pharmaceutical Co., Ltd. Fused benzeneoxyacetic acid derivatives as PGl2 receptor agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1366514A1 (ru) * 1986-01-28 1988-01-15 Днепропетровский химико-технологический институт им.Ф.Э.Дзержинского Способ получени производных N-арил-5-ариламидо-4,6-диметилпиридона-2
DE3837809A1 (de) * 1988-11-08 1990-05-10 Merck Patent Gmbh Tetralinderivate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542203A2 (en) * 1991-11-11 1993-05-19 Ono Pharmaceutical Co., Ltd. Fused benzeneoxyacetic acid derivatives as PGl2 receptor agonists

Also Published As

Publication number Publication date
AU1861895A (en) 1995-09-25
WO1995024393A1 (en) 1995-09-14
HU9602466D0 (en) 1996-11-28
TW282456B (https=) 1996-08-01
KR970701698A (ko) 1997-04-12
DE69522676T2 (de) 2002-04-18
GR3037080T3 (en) 2002-01-31
HK1013289A1 (en) 1999-08-20
ATE205479T1 (de) 2001-09-15
HUT75226A (en) 1997-04-28
AU688871B2 (en) 1998-03-19
US5763489A (en) 1998-06-09
ES2160156T3 (es) 2001-11-01
EP0749424A1 (en) 1996-12-27
PT749424E (pt) 2002-03-28
HU224822B1 (en) 2006-02-28
KR100383305B1 (ko) 2003-11-01
JP3245864B2 (ja) 2002-01-15
US5863918A (en) 1999-01-26
EP0749424B1 (en) 2001-09-12
DE69522676D1 (de) 2001-10-18
JPH09509958A (ja) 1997-10-07
CA2185104A1 (en) 1995-09-14
RU2155188C2 (ru) 2000-08-27
DK0749424T3 (da) 2001-11-26
CN1147250A (zh) 1997-04-09

Similar Documents

Publication Publication Date Title
CN1057522C (zh) 作为前列腺素i2激动剂的萘衍生物
CN1090184C (zh) 杂环化合物及其制备方法
CN1045770C (zh) 制备１－联苯甲基咪唑衍生物的方法
CN1045768C (zh) 一种血管紧张肽ⅱ拮抗剂化合物及其制备方法和用途
CN1293076C (zh) 过氧化物酶体增殖剂应答性受体δ的活化剂
CN1193018C (zh) 杂环衍生物及其医药用途
CN1067387C (zh) 1,2,3,4－四氢喹喔啉二酮衍生物
CN1196726A (zh) 4,5－二芳基噁唑衍生物
CN1077953A (zh) 乙酸衍生物
CN1212691A (zh) 三环化合物及其制备和用途
CN1328550A (zh) 作为前列腺素e2激动剂或拮抗剂的噁唑化合物
CN1193966A (zh) 芳族化合物和含有它们的药物组合物
CN1084846A (zh) 乙醇胺衍生物
CN1155599C (zh) 三环三唑并苯并氮杂�衍生物、用于制备该衍生物的方法和抗变态反应剂
CN1083475A (zh) 乙酸衍生物
CN1296369C (zh) 制备7－二氢异吲哚喹诺酮羧酸衍生物及其中间体的方法
CN1056685A (zh) 吲哚衍生物及其制备方法
CN1112363A (zh) 制备5，8-二氢萘醌衍生物的方法，新的5，8-二氢萘醌衍生物和它们作为抗癌药的用途
CN1090282A (zh) 苯稠合羟基取代的环烷基和杂环化合物的磺酰胺衍生物
CN1489582A (zh) 二氢化萘衍生物及包含该衍生物作为活性成分的药物
CN1319095A (zh) 咪唑化合物及其作为腺苷脱氨酶抑制剂的用途
CN101065364A (zh) 新的嘧啶衍生物和它们作为PPAR－α调节剂的应用
CN1020899C (zh) 吡咯烷衍生物的制备方法
CN1284060A (zh) 新的金属蛋白酶抑制剂
CN1599717A (zh) 具有稠环基团的环二胺化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee